塔綠班不敢面對的真相就是，高端自己在文章提到自己沒有保護力資料，只能說自己中和
抗體很多（跟之前大家就已經知道的故事差在哪？）
然後，高端自己也提到，自己是在中和抗體最高的時間點取血清（跟愛刷存在感的某前版
主一樣），但血清之後變低還有沒有保護效果不知道，因為牽扯到t細胞的免疫反應，無
法得知。（也就跟大家說的一樣，沒有保護力資料，根本是假的）
不過塔綠班還是高潮的很爽啦！嘻嘻
A limitation of our study is that the sera were taken 4 weeks after the second
shot of MVC-COV1901 when immunity has peaked and only just started to wane. T
herefore, we could not evaluate the impact of waning immunity on the neutraliz
ing capacity against the variants. The study cannot evaluate the role of T-cel
l responses elicited by the vaccine as it was reported that the T-cell respons
es to immunization may confer heterotypic coverage and are less affected by Vo
Cs [31].
COVID-19 vaccines in phase 3 clinical trials in South Africa when the Beta var
iant became predominant showed considerably high protection against severe cli
nical endpoints, while overall efficacy is lower than at sites outside of Sout
h Africa [32].
Since there are no correlates of protection being published for emerging varia
nts, it warrants further study on how the reduced neutralizing titers will tra
nslate to clinical endpoints. We are currently conducting a randomized, double
-blind, placebo-controlled phase 2 study for safety and immunogenicity of MVC-
COV1901 with >3800 subjects (NCT04695652). The samples from the phase 2 trial
would allow us to further investigate the effects of variants on neutralizing
titers by using a larger set of samples and newer variants.